Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

REGN1909

Phase 3Small molecule

REGN1909 is one of 33 small molecule programs targeting Allergy. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

32

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

AllergyPhase 3

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Allergy

#DrugCompanyPhaseTrials

Flovent

Clarinex

OOrganon and Co

Xolair

REGN5715

REGN5713

Rhapsido

Ligelizumab

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Adrenaline

SSamson Clinical Operations Pty Ltd

Elspar

DDutch Childhood Oncology Group

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergy1 trial

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

Completed· Regeneron logo

Regeneron·Phase 3·NCT06602726·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for REGN1909. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN1909 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN1909. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Regeneron

Related News